nalbuphine hydrochloride + flurbiprofen axetil

Anricafen is a fixed-dose combination analgesic consisting of **nalbuphine hydrochloride** and **flurbiprofen axetil**. Nalbuphine is a synthetic opioid agonist-antagonist that acts as a potent agonist at the kappa-opioid receptor and an antagonist at the mu-opioid receptor, providing effective analgesia with a lower risk of mu-mediated side effects such as respiratory depression and pruritus. Flurbiprofen axetil is an injectable lipid emulsion prodrug of the non-steroidal anti-inflammatory drug (NSAID) flurbiprofen, which inhibits cyclooxygenase (COX) enzymes to reduce the synthesis of inflammatory prostaglandins. By combining these two agents, Anricafen utilizes a multimodal approach to pain management, targeting both central opioid pathways and peripheral inflammatory mediators. It is primarily developed for the treatment of moderate to severe postoperative pain, particularly following abdominal surgeries, where it is often evaluated for its ability to provide superior comfort and safety compared to traditional mu-opioid agonists like morphine.

Brand names

Anricafen

Other names

Anricafennalbuphine/flurbiprofen axetil安瑞卡芬